One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Access
PDF Availablehttps://doi.org/10.1093/annonc/mdx367.043
Copy DOI
Export
Save
Share
Cite Journal: Annals of Oncology |  Publication Date: Sep 1, 2017 |
 Citations: 10 |  License type: publisher-specific-oa |
Affiliation: Fox Chase Cancer Center, University of Colorado Denver, Cambridge University Hospitals NHS Foundation Trust, University of Oxford, The Christie NHS Foundation Trust, Newcastle University, Mid Essex Hospital Services NHS Trust, University Hospitals Bristol NHS Foundation Trust, Royal Marsden Hospital, St. Luke's Hospital, University of California, San Francisco, Millennium Engineering and Integration (United States), Takeda (United States), AstraZeneca (United States), South Texas Accelerated Research Therapeutics
410P - Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
